About

Dr. Dan Zabrowski has served as a director of Actuate Therapeutics since March 2021 and chairs its compensation committee. He has been a Venture Partner of Decheng Capital, a private investment firm, since July 2016. He previously spent more than 20 years at Roche in a range of global leadership roles, including Global Head of Regulatory Affairs, Global Head of Development Operations, Global Head of Roche Pharma Partnering, President of Ventana Medical Systems and President of the Roche Sequencing Unit, and earlier held positions at Syntex, Fujisawa (now Astellas) and G.D. Searle. He has served on the boards of several public and private biotechnology companies, including Apexigen, BeyondSpring, Nimble Therapeutics and Endogena Therapeutics. Dr. Zabrowski earned a Ph.D. in Organic Chemistry from Indiana University, Bloomington, and a B.A. in Chemistry from Saint Louis University.

Roles

Actuate Therapeutics, Inc.
Director · Current role
March 2021–present
Decheng Capital
Venture Partner
2016 - present
Roche
Global Head of Regulatory Affairs; President, Ventana Medical Systems; President, Roche Sequencing Unit
1994 - 2016

Director Compensation

FY 2025
Fees earned or paid in cash
$56,000
ComponentAnnual cash retainers and committee/chair fees earned in 2025
Option awards
$103,995
ComponentAnnual stock option grant (15,000 shares, May 22, 2025), ASC 718 grant-date fair value
Total
$159,995

Also at Actuate Therapeutics, Inc.

Related

See how Top Bucket AI works for your firm

Request Demo
Top Bucket AI Research

Stay ahead of private markets

Research and market intelligence for private-markets professionals.

✓

You're subscribed.

Thanks for signing up.